Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciad362 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Jordan J Feld und 6 weiteren Autor:innen. Beteiligte Einrichtung: Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Hepatitis C, Vaccines, Hepatitis C, Chronic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, US National Institutes of Health.
Abstract (Originalsprache)
The design of a clinical trial for a controlled human infection model (CHIM) to accelerate hepatitis C virus (HCV) vaccine development requires careful consideration. The design of a potential approach to HCV CHIM is outlined, involving initial sentinel cohorts to establish the safety and curability of the viral inoculum followed by larger cohorts to establish the spontaneous clearance rate for each inoculum. The primary endpoint would be HCV clearance by 24 weeks post-inoculation, recognizing that the prevention of chronic infection would be the primary goal of HCV vaccine candidates. Additional considerations are discussed, including the populations to be enrolled, the required monitoring approach, indications for antiviral therapy, and the required sample size for different CHIM approaches. Finally, safety considerations for CHIM participants are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Canada.
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Université de Montréal, Montreal, Canada.
- Kirby Institute, University of New South Wales, Sydney, Australia.
- Liver Diseases Branch, National Institutes of Diabetes, Digestive, and Kidney Diseases, Bethesda, Maryland, USA.
- Department of Medicine, Erasmus University, Rotterdam, The Netherlands.
- Department of Medicine, The Johns Hopkins University, Baltimore, Maryland, USA.
ORCID-Profile: Jordan J Feld
Förderung
- NIDA NIH HHS
- US National Institutes of Health
Zitieren
APA
Feld, J. J., Bruneau, J., Dore, G. J., Ghany, M. G., Hansen, B., Sulkowski, M., & Thomas, D. L. (2023). Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad362
Vancouver
Feld JJ, Bruneau J, Dore GJ, Ghany MG, Hansen B, Sulkowski M, et al. Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad362
BibTeX
@article{Feld2023,
author = {Feld, Jordan J and Bruneau, Julie and Dore, Gregory J and Ghany, Marc G and Hansen, Bettina and Sulkowski, Mark and Thomas, David L},
title = {Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciad362}
}
EUVIMED